Novel advances in pancreatic cancer treatment

References

• Evans DB, Abbruzzese JL, Willett CG. Cancer of the Pancreas. In: Principles and Practice of Oncology (6th Edition). DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, Philadelphia, USA, 1126–1116 (2001).
   Google Scholar
• Brand R. The diagnosis of pancreatic cancer. Cancer J.7(4), 287–297 (2001).
   PubMedGoogle Scholar
• Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer J.78(3 Suppl.), 654–663 (1996).
   Google Scholar
• Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA253(14), 2061–2067 (1985).
   PubMed Web of Science ®Google Scholar
• Ducreux M, Rougier P, Pignon JP et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol.13(8), 1185–1191 (2002).
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg.230(6), 776–782 (1999).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol.25(18), 2607–2615 (2007).
   PubMed Web of Science ®Google Scholar
• Ychou M, Desseigne F, Guimbaud R et al. Randomized Phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Slebos RJ, Hoppin JA, Tolbert PE et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol. Biomarkers Prev.9(11), 1223–1232 (2000).
   PubMed Web of Science ®Google Scholar
• Brunner TB, Cengel KA, Hahn SM et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-ras. Cancer Res.65(18), 8433–8441 (2005).
   PubMedGoogle Scholar
• Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol. Cancer Res.3(7), 413–423 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18(1), 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res.62(7), 1996–2003 (2002).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol.23(31), 8033–8040 (2005).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Presented at: 2007 GI ASCO Annual Meeting. Orlando, FL, USA, 19–21 January 2007.
   Google Scholar
• Solorzano CC, Baker CH, Bruns CJ et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm.16(5), 359–370 (2001).
   PubMed Web of Science ®Google Scholar
• Kuo T, Fitzgerald A, Kaiser H, Sikic BI, Fisher GA. A Phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. Presented at: 2006 GI ASCO. San Francisco, CA, USA, 26–28 January 2006.
   Google Scholar
• Wallace A, Locker G, Nattam S et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a Phase II trial of the University of Chicago Phase II Consortium. Presented at: 2007 GI ASCO Annual Meeting. Orlando, FL, USA, 19–21 January 2007.
   Google Scholar
• Spano J, Chodkiewicz C, Maurel J et al. A randomized Phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a Phase I component. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res.11(1), 407–409 (2005).
   PubMedGoogle Scholar
• Mulay M, Limentani SA, Carroll M et al. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination Phase I clinical trial of patients with advanced solid tumors. Presented at: 2006 ASCO Annual Meeting. Atlanta, GA, USA, 2–6 June 2006.
   Google Scholar
• Dupont J, Rothenberg ML, Spriggs DR et al. Safety and pharmacokinetics of intravenous VEGF Trap in a Phase I clinical trial of patients with advanced solid tumors. Presented at: 2005 ASCO Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta1333(3), F217–F248 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Fabbro D. Therapeutically targeted anti-cancer agents: inhibitors of receptor tyrosine kinases. Mini. Rev. Med. Chem.4(3), 273–283 (2004).
   PubMedGoogle Scholar
• Craven RJ, Lightfoot H, Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg. Oncol.12(1), 39–49 (2003).
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol.29(5 Suppl. 14), 31–37 (2002).
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res.6(5), 1936–1948 (2000).
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol.22(13), 2610–2616 (2004).
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathway and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther.1(10), 777–783 (2002).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J. Clin. Oncol.25(15), 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Ko AH, Dito E, Schillinger B et al. A Phase II study of bevacizumab (BEV) and erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic adenocarcinoma of the pancreas (PanCa). Presented at: 2007 GI ASCO Annual Meeting. Orlando, FL, USA, 19–21 January 2007.
   Google Scholar
• Safran H, Iannitti D, Miner T et al. GW572016/gemcitabine and GW572016/gemcitabine/oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. Presented at: 2006 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2006.
   Google Scholar
• Saxby AJ, Nielsen A, Scarlett CJ et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuplody and survival. Am. J. Surg. Pathol.29(9), 1125–1134 (2005).
   PubMedGoogle Scholar
• Safran H, Iannitti D, Ramanathan R et al. Herceptin and gemcitabine for metastatic pancreatic cancer that overexpress HER-2/neu. Cancer Invest.22(5), 706–712 (2004).
   PubMed Web of Science ®Google Scholar
• Graeven U, Kremer B, Südhoff T et al. Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Br. J. Cancer94(9), 1293–1299 (2006).
   PubMed Web of Science ®Google Scholar
• Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev.22(4), 337–358 (2003).
   PubMed Web of Science ®Google Scholar
• Grant S, Dent P. Kinase inhibitors and cytotoxic drug resistance. Clin. Cancer Res.10(7), 2205–2207 (2004).
   PubMedGoogle Scholar
• Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery134(2), 221–226 (2003).
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res.10(7), 2307–2318 (2004).
   PubMed Web of Science ®Google Scholar
• Yezhelyev MV, Koehl G, Guba M et al. Inhibition of Src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res.10(23), 8028–8036 (2004).
   PubMed Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res.7(5), 1429–1437 (2001).
   PubMed Web of Science ®Google Scholar
• Whitehead RP, McCoy S, Rivkin SE et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest. New Drugs.24(6), 515–520 (2006).
   PubMed Web of Science ®Google Scholar
• Khong HT, Dreisbach L, Kindler HL et al. A Phase II study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Ueno H, Okusaka T, Furuse J et al. A multicenter Phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Chiorean EG, Dragovich T, Hamm J et al. Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Cusack JC, Liu R, Xia L, Neuteboom S, Palladino M. Salinosporamide A, a novel orally active proteasome inhibitor NPI-0052 enhances tumoricidal response to multidrug chemo- and molecular therapy regimens in a pancreatic cancer xenograft model. Presented at: 2006 GI ASCO Annual Meeting. San Francisco, CA, USA, 19–21 January 2006.
   Google Scholar
• McGartland LP, Mulcahy MF, Rademaker A et al. Phase I/II study of imatinib mesylate and gemcitabine for advanced pancreas cancer. Presented at: 2006 GI ASCO Annual Meeting. San Francisco, CA, USA, 19–21 January 2006.
   Google Scholar
• Nugent FW, Cunningham C, Barve MA et al. Phase II study of talabostat/gemcitabine in Stage IV pancreatic cancer. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Evans T, Ramanathan RK, Yazji S et al. Final results from cohort 1 of a Phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Ferrari V, Valcamonico F, Amoroso V et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a Phase II trial. Cancer Chemother. Pharmacol.57(2), 185–190 (2006).
   Google Scholar
• Cox JV, Cartwright T, Neubauer M et al. A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer. Presented at: 2006 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2006.
   Google Scholar